| Dr Jessica Lynette Hurwitz, DNP, CNM, ARNP | |
|
903 Medical Center Dr, Arlington, WA 98223 | |
| (360) 435-0242 | |
| (360) 435-9135 |
| Full Name | Dr Jessica Lynette Hurwitz |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 7 Years |
| Location | 903 Medical Center Dr, Arlington, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174046536 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | AP60773712 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Public Hospital Dist No 1 Skagit | 6800793522 | 248 |
News Archive
Innovation doesn't come easy" says Steve Atkinson, Systagenix CEO "and neither do great brands, yet our team have been responsible for many innovations within this field over the last four decades. We are now introducing the world's first rapid point of care test in wound care to help clinicians choose the most appropriate dressings and therapies for their patients and monitor their efficacy over time.
The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.
The Coalition for a Competitive Pharmaceutical Market (CCPM), its allied organizations, representing several hundred million Americans, join experts from the medical and research communities, economists and thought leaders appealing to Congress to fix the excessive 12-year market exclusivity and ever-greening provisions for biologics or drop it altogether.
Integra LifeSciences announced today a major milestone in the commercialization of the Vu a-POD™ anterior lumbar intervertebral body fusion (ALIF) device. Launched in the U.S. in early 2009, the Vu a-Pod™ fusion device has now been implanted in over 800 patients in the U.S.
A team of researchers leading a pan-European organic food project also recommends that shoppers tell retailers if they are satisfied or not with the products and the information provided on their labels.
› Verified 5 days ago
| Entity Name | Public Hospital Dist No 1 Skagit |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023332749 PECOS PAC ID: 6800793522 Enrollment ID: O20040309001059 |
News Archive
Innovation doesn't come easy" says Steve Atkinson, Systagenix CEO "and neither do great brands, yet our team have been responsible for many innovations within this field over the last four decades. We are now introducing the world's first rapid point of care test in wound care to help clinicians choose the most appropriate dressings and therapies for their patients and monitor their efficacy over time.
The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.
The Coalition for a Competitive Pharmaceutical Market (CCPM), its allied organizations, representing several hundred million Americans, join experts from the medical and research communities, economists and thought leaders appealing to Congress to fix the excessive 12-year market exclusivity and ever-greening provisions for biologics or drop it altogether.
Integra LifeSciences announced today a major milestone in the commercialization of the Vu a-POD™ anterior lumbar intervertebral body fusion (ALIF) device. Launched in the U.S. in early 2009, the Vu a-Pod™ fusion device has now been implanted in over 800 patients in the U.S.
A team of researchers leading a pan-European organic food project also recommends that shoppers tell retailers if they are satisfied or not with the products and the information provided on their labels.
› Verified 5 days ago
| Entity Name | Olympia Obstetrics & Gynecology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922045848 PECOS PAC ID: 8426086802 Enrollment ID: O20050727000693 |
News Archive
Innovation doesn't come easy" says Steve Atkinson, Systagenix CEO "and neither do great brands, yet our team have been responsible for many innovations within this field over the last four decades. We are now introducing the world's first rapid point of care test in wound care to help clinicians choose the most appropriate dressings and therapies for their patients and monitor their efficacy over time.
The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.
The Coalition for a Competitive Pharmaceutical Market (CCPM), its allied organizations, representing several hundred million Americans, join experts from the medical and research communities, economists and thought leaders appealing to Congress to fix the excessive 12-year market exclusivity and ever-greening provisions for biologics or drop it altogether.
Integra LifeSciences announced today a major milestone in the commercialization of the Vu a-POD™ anterior lumbar intervertebral body fusion (ALIF) device. Launched in the U.S. in early 2009, the Vu a-Pod™ fusion device has now been implanted in over 800 patients in the U.S.
A team of researchers leading a pan-European organic food project also recommends that shoppers tell retailers if they are satisfied or not with the products and the information provided on their labels.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica Lynette Hurwitz, DNP, CNM, ARNP 1400 E Kincaid St, Mount Vernon, WA 98274-4127 Ph: (360) 428-2500 | Dr Jessica Lynette Hurwitz, DNP, CNM, ARNP 903 Medical Center Dr, Arlington, WA 98223 Ph: (360) 435-0242 |
News Archive
Innovation doesn't come easy" says Steve Atkinson, Systagenix CEO "and neither do great brands, yet our team have been responsible for many innovations within this field over the last four decades. We are now introducing the world's first rapid point of care test in wound care to help clinicians choose the most appropriate dressings and therapies for their patients and monitor their efficacy over time.
The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.
The Coalition for a Competitive Pharmaceutical Market (CCPM), its allied organizations, representing several hundred million Americans, join experts from the medical and research communities, economists and thought leaders appealing to Congress to fix the excessive 12-year market exclusivity and ever-greening provisions for biologics or drop it altogether.
Integra LifeSciences announced today a major milestone in the commercialization of the Vu a-POD™ anterior lumbar intervertebral body fusion (ALIF) device. Launched in the U.S. in early 2009, the Vu a-Pod™ fusion device has now been implanted in over 800 patients in the U.S.
A team of researchers leading a pan-European organic food project also recommends that shoppers tell retailers if they are satisfied or not with the products and the information provided on their labels.
› Verified 5 days ago
Cindy L Beske, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 903 Medical Center Dr, Arlington, WA 98223 Phone: 360-435-0242 Fax: 360-435-9135 |